Sort
10,766 grants matching “checkpoint inhibitor”
Breast and Ovarian Cancer Program - 08
$36,867Vered Stearns · Johns Hopkins University · P30 · FY2017 · CA
Role of Neurogenesis in Depression and Antidepressant Efficacy
$36,846Jennifer Onksen · University Of Pennsylvania · F31 · FY2010 · MH
Examining the impact of laboratory housing temperature on murine CD28 and the response to anti-PD-1
$36,792Caitlin M James · Roswell Park Cancer Institute Corp · F31 · FY2024 · CA
Lymphoma & Leukemia Research Program (Project-007)
$36,782Ronald Levy · Stanford University · P30 · FY2016 · CA
Myeloid cell driven immune suppression in pancreatic cancer
$36,674Rosa Elena Menjivar · University Of Michigan At Ann Arbor · F31 · FY2021 · CA
Identifying the Role of Tumor Cell Intrinsic DNMT1 in Anti-Tumor Immunity in Pancreatic Ductal Adenocarcinoma
$36,670Erin Elizabeth Hollander · University Of Pennsylvania · F30 · FY2024 · CA
Development of a tumor-activated IL12 prodrug to treat solid tumors
$36,545Benjamin Moon · Ut Southwestern Medical Center · F30 · FY2021 · CA
Validation of WEE1 kinase as a clinical target in KRAS-mutant pancreatic cancer
$36,523John Nathaniel Diehl · Univ Of North Carolina Chapel Hill · F30 · FY2019 · CA
p27pTpT drives cancer-promoting inflammation and shapes the tumor microenvironment (TME) toward a more tumor-permissive state in vivo
$36,494Seyedehfatemeh Razavipour · Georgetown University · F99 · FY2023 · CA
The relative impact of the Hippo and RB tumor suppressor pathways inhibition on the ovarian cancer progression
$36,476Fatmata Sesay · Virginia Commonwealth University · F31 · FY2020 · CA
Epigenetic Regulation by Histone Modifiers in Development and Cancer
$36,432Christie Ching-Lin Sze · Northwestern University At Chicago · F99 · FY2019 · CA
Investigating the Roles of Phospholipase A2s and Diacylglycerol Signaling in Ferroptosis
$36,311Annie J Lin · Columbia University Health Sciences · F30 · FY2024 · CA
p27pTpT drives cancer-promoting inflammation and shapes the tumor microenvironment (TME) toward a more tumor-permissive state in vivo
$36,274Seyedehfatemeh Razavipour · Georgetown University · F99 · FY2024 · CA
Design and Delivery of Neoantigen-based Tumor Vaccines
$36,185Christof Chiu Smith · Univ Of North Carolina Chapel Hill · F30 · FY2019 · CA
Rational approaches to melanoma therapy
$36,000Meenhard Herlyn · Wistar Institute · U54 · FY2019 · CA
Transcriptional Regulation of Peripheral Immune Cells as a Modulator of Melanoma Immunotherapy Resistance and Toxicity
$35,985Kelsey R Monson · New York University School Of Medicine · F99 · FY2022 · CA
The relative impact of the Hippo and RB tumor suppressor pathways inhibition on the ovarian cancer progression
$35,972Fatmata Sesay · Virginia Commonwealth University · F31 · FY2019 · CA
PD-1 blockade effects on bone strength and metastatic progression
$35,870Gwenyth Jean Joseph · Vanderbilt University · F99 · FY2024 · CA
Intratumoral plasma cells in MPNST response to CDK4/6 targeted therapy and sensitization to immune checkpoint blockade
$35,771Joshua J Lingo · University Of Iowa · F31 · FY2024 · CA
Elucidating and Targeting EZH2 in the DNA Damage Response in Small Cell Lung Cancer
$35,703Allyson Koyen · Emory University · F31 · FY2020 · CA
Design and Delivery of Neoantigen-based Tumor Vaccines
$35,693Christof Chiu Smith · Univ Of North Carolina Chapel Hill · F30 · FY2018 · CA
Project 1: Developing Immune Checkpoint Controlled Release Biomaterials for Caner Immunotherapy
$35,688Richard Mu · Tennessee State University · U54 · FY2022 · CA
Role of cell-intrinsic effects of PD-L1 in carcinogenesis
$35,644Anand Kornepati · University Of Texas Hlth Science Center · F30 · FY2022 · CA
Dissecting the roles of a novel immune-checkpoint receptor complex in driving T cell dysfunction in cancers
$35,609Cassandra Gilmour · Cleveland Clinic Lerner Com-Cwru · F31 · FY2022 · CA
Molecular indicators of treatment responses and adverse events in melanoma
$35,541Sarah Martinez Roth · Georgetown University · F31 · FY2018 · CA